ATE483972T1 - Reagenzien und verfahren für krebsprognose und pathologische einstufung - Google Patents

Reagenzien und verfahren für krebsprognose und pathologische einstufung

Info

Publication number
ATE483972T1
ATE483972T1 AT07757161T AT07757161T ATE483972T1 AT E483972 T1 ATE483972 T1 AT E483972T1 AT 07757161 T AT07757161 T AT 07757161T AT 07757161 T AT07757161 T AT 07757161T AT E483972 T1 ATE483972 T1 AT E483972T1
Authority
AT
Austria
Prior art keywords
reagents
methods
cancer prognosis
pathological grading
grading
Prior art date
Application number
AT07757161T
Other languages
English (en)
Inventor
Gary Pestano
Linda Samadzadeh
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of ATE483972T1 publication Critical patent/ATE483972T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07757161T 2006-02-16 2007-02-16 Reagenzien und verfahren für krebsprognose und pathologische einstufung ATE483972T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77456306P 2006-02-16 2006-02-16
PCT/US2007/062362 WO2007095644A2 (en) 2006-02-16 2007-02-16 Reagents and methods for cancer prognosis and pathological staging

Publications (1)

Publication Number Publication Date
ATE483972T1 true ATE483972T1 (de) 2010-10-15

Family

ID=38335516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07757161T ATE483972T1 (de) 2006-02-16 2007-02-16 Reagenzien und verfahren für krebsprognose und pathologische einstufung

Country Status (10)

Country Link
US (2) US20070207489A1 (de)
EP (2) EP1984735B1 (de)
JP (1) JP5143026B2 (de)
CN (2) CN101384901A (de)
AT (1) ATE483972T1 (de)
AU (1) AU2007214427B2 (de)
CA (1) CA2642542C (de)
DE (1) DE602007009645D1 (de)
ES (1) ES2354181T3 (de)
WO (1) WO2007095644A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US9697582B2 (en) 2006-11-16 2017-07-04 Visiopharm A/S Methods for obtaining and analyzing images
WO2010017822A1 (en) 2008-08-15 2010-02-18 Visiopharm A/S A method and a system for determining a target in a biological sample by image analysis
CA2690612C (en) 2007-05-14 2016-07-05 Historx, Inc. Compartment segregation by pixel characterization using image data clustering
ES2599902T3 (es) 2007-06-15 2017-02-06 Novartis Ag Sistema y método de microscopio para obtener datos de muestra normalizados
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009029810A1 (en) 2007-08-31 2009-03-05 Historx, Inc. Automatic exposure time selection for imaging tissue
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
JP5551702B2 (ja) 2008-09-16 2014-07-16 ヒストロックス，インコーポレイテッド． バイオマーカー発現の再現性のある定量
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2010066252A1 (en) * 2008-12-09 2010-06-17 Dako Denmark A/S Method for evaluating pre-treatment
CA2749601C (en) 2009-01-14 2020-07-21 Stephen M. Hewitt Ratio based biomarkers and methods of use thereof
EP2542696B1 (de) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Theranostik-biomarker
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
CN102939538A (zh) * 2010-05-07 2013-02-20 霍夫曼-拉罗奇有限公司 用于离体检测细胞的诊断方法
CN101876659B (zh) * 2010-06-29 2013-02-13 同济大学 用于检测肿瘤的量子点试剂盒
EP2619329B1 (de) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direkte erfassung, amplifikation und sequenzierung einer ziel-dna unter verwendung immobilisierter primer
US9410207B2 (en) * 2011-12-30 2016-08-09 Abbott Molecular Inc. Method and compositions for detecting epidermal growth factor receptor variant forms in cancer cells
JP6619339B2 (ja) * 2013-08-30 2019-12-11 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ポリープ再発
EP3100054B1 (de) * 2014-01-28 2022-02-23 Quest Diagnostics Investments Incorporated Verfahren und zusammensetzungen zum nachweis eines adenoma-adenokarzinom-übergangs bei krebs
CN103882139B (zh) * 2014-04-04 2015-06-03 上海赛安生物医药科技有限公司 一种用于化疗方案选择的多重基因检测试剂盒
US10746740B2 (en) 2015-01-22 2020-08-18 Konica Minolta, Inc. Biological substance quantitation method, pathological diagnosis support system, and recording medium storing computer readable program
US10517823B1 (en) * 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
CN107688092B (zh) * 2017-08-18 2020-05-19 国家纳米科学中心 一种用于癌症患者预后评估的方法
CN111819443A (zh) 2018-02-28 2020-10-23 日东纺绩株式会社 从固定化细胞或ffpe组织切片脱离增强抗原性的细胞核的方法以及用于该方法的抗原活化剂及试剂盒

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US6872817B1 (en) * 1986-01-16 2005-03-29 The Regents Of The Univ. Of California Method of staining target interphase chromosomal DNA
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6649359B2 (en) * 2000-06-01 2003-11-18 The Brigham & Women's Hospital, Inc. Diagnosis of endometrial precancers
EP1360496A4 (de) * 2001-02-16 2005-03-09 Immunivest Corp Verfahren und reagenzien zur schnellen und effizienten isolierung zirkulierender krebszellen
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
AU2003251597A1 (en) * 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
US7576074B2 (en) * 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
AU2003291736A1 (en) * 2002-11-05 2004-06-03 Cell Signaling Technology, Inc. Methods and materials for examining pathways associated with glioblastoma progression
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
DE10345021A1 (de) * 2003-09-23 2005-05-04 Univ Potsdam Verfahren zur nichtinvasiven Früherkennung von Dickdarmkrebs und/oder Darmkrebsvorläuferzellen
CA2569079A1 (en) * 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
EP3042964A1 (de) * 2004-06-04 2016-07-13 Genentech, Inc. Egfr-mutationen
AU2005294214A1 (en) * 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use
EP2473495A1 (de) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmazeutische verbindungen

Also Published As

Publication number Publication date
CA2642542C (en) 2012-09-25
AU2007214427A1 (en) 2007-08-23
DE602007009645D1 (de) 2010-11-18
CN104749378A (zh) 2015-07-01
JP5143026B2 (ja) 2013-02-13
CN101384901A (zh) 2009-03-11
CA2642542A1 (en) 2007-08-23
WO2007095644A2 (en) 2007-08-23
EP2290361A1 (de) 2011-03-02
EP1984735B1 (de) 2010-10-06
JP2009527740A (ja) 2009-07-30
AU2007214427B2 (en) 2011-11-10
US20100184099A1 (en) 2010-07-22
EP1984735A2 (de) 2008-10-29
US20070207489A1 (en) 2007-09-06
WO2007095644A3 (en) 2007-12-27
ES2354181T3 (es) 2011-03-10

Similar Documents

Publication Publication Date Title
ATE483972T1 (de) Reagenzien und verfahren für krebsprognose und pathologische einstufung
DE602006002809D1 (de) Verfahren zur erkennung eines ovarialkarzinoms
EP1969363A4 (de) Verfahren und markerkombinationen zum screening auf eine veranlagung zu lungenkrebs
EP1897940A4 (de) Zusammensetzung und verfahren zur diagnose von speiseröhrenkrebs sowie der metastasierung von speiseröhrenkrebs
IN2013CN01129A (de)
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
DE112006001755A5 (de) EU/TB-Chelat-basiertes fluoreszenzspektroskopisches Verfahren zum Nachweis von Analyten
EP1991701A4 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von krebs
DK2211180T3 (da) Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer
ATE410524T1 (de) Verfahren und nukleinsäuren für die analyse von zellulären proliferationsstörungen
TWI317811B (de)
WO2013057581A8 (en) Composite biomarker for non-invasive screening, diagnosis and prognosis of colorectal cancer
EP1599603A4 (de) Diagnose- und prognoseverfahren von pankreaskrebs
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
EA201370063A1 (ru) Фосфолипидом рака
ATE534905T1 (de) Cop1-moleküle und verwendungen davon
ATE557276T1 (de) Spezifisches verfahren zum krebsnachweis
ATE408839T1 (de) Tumor marker für urothelialen krebs
WO2010009074A3 (en) Method for predicting and detecting tumor metastasis
WO2007082073A3 (en) Biomarkers for oral tongue cancer metastasis and extracapsular spread (ecs)
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
ATE433158T1 (de) System und verfahren zur erkennung der breite eines datenbusses
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
WO2008104985A3 (en) Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers
DE112007003222A5 (de) Prognostische Marker für die Klassifizierung von kolorektalen Karzinomen basierend auf Expressionsprofilen von biologischen Proben

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties